You are here: Industry Insights > Ambrx

News List

Ambrx gets orphan drug designation for gastric cancer treatment ARX788 pharmaceutical-business-review
March 23, 2021
The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.
FDA grants ARX788 fast track designation for HER2-positive metastatic breast cancer pharmaceutical-business-review
January 07, 2021
Ambrx announced that the US Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2 based ...
Ambrx, BeiGene to develop next-generation biologics biospectrumasia
March 08, 2019
Ambrx to receive an upfront payment of $10 million to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates in this collaboration with BeiGene
BeiGene and Ambrx form R&D alliance for new biologics pharmaceutical-technology
March 08, 2019
China-based immuno-oncology drugs maker BeiGene and American biopharmaceutical firm Ambrx have formed a research and development (R&D) partnership to develop next-generation biologic drugs.
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics pharmafocusasia
March 07, 2019
Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of innovative protein therapeutics and BeiGene, Ltd., a commercial-stage biopharmaceutical company...
TRACON Pharma, Ambrx Ink Deal Up to $143.5M for TRC105 biospace
December 22, 2017
Total Value of Deal up to $143.5 Million for TRACON, Including a $3 Million Upfront Payment and Potential Milestones, Plus Potential Tiered Royalties